Health TrialsbyHealthPanel

"Xijiang Project" Screening Cohort for NPC

ConditionsNasopharyngeal Carcinoma (NPC)Screening
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-69
SponsorMing-Yuan Chen

About this trial

The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and family history, dietary and lifestyle habits, and geographical environmental factors; a biobank of blood, tissue fluid, swabs, etc., for Epstein-Barr virus, tumors, and genetics; a clinical examination database including nasopharyngoscopy, imaging, pathology, and other examinations; and databases of Epstein-Barr virus and human genetic sequencing, etc.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Residents with a definite native place;

Aged 30 and 69 years at screening;

Capable of long-term cooperation with screening and follow-up.

Disqualifiers

Known severe cardiovascular, liver or kidney disease, or neuropsychiatric disorders;

History of previous malignant tumors;

Severe autoimmune diseases or immunodeficiency;

Females with a positive pregnancy test at screening;

Trial population

Residents with a definite native place, aged 30 and 69 years at screening, and capable of long-term cooperation with screening and follow-up.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • EBV antibodies test

    Diagnostic test

    Test for VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.

  • EBV DNA test

    Diagnostic test

    quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.

  • epidemiological information survey

    Other intervention

    epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.

  • Clinical examinations for high-risk participants

    Other intervention

    nasopharyngoscopy, head and neck MRI.

  • EBV and human genetic sequencing

    Other intervention

    EB virus and human genetic sequencing for plasma, etc.

Treatment groups

1,000,000 Participants
are divided into 1 treatment group
Group A: Screening cohort of nasopharyngeal carcinoma5 interventions

Trial outcomes

Primary outcomes

1

A data platform for an NPC screening cohort

A data platform, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information.

Time frame
At screening, 3 years and 10 years thereafter

Secondary outcomes

1

Prevalence and incidence rate of nasopharyngeal carcinoma

Endoscopy combined with or without biopsy is performed to evaluate the prevalence and rate of new cases of nasopharyngeal carcinoma, in a cohort study, and to identify the associated factors related with nasopharyngeal carcinoma.

Time frame
At screening, 3 years and 10 years thereafter
2

Nasopharyngeal Carcinoma Death Rates

Nasopharyngeal Carcinoma deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Time frame
At screening, 3 years and 10 years thereafter
3

Death Rates From All Causes

Deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Time frame
At screening, 3 years and 10 years thereafter

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ming-Yuan Chen

Lead sponsor

Sun Yat-sen University

Sponsor institution

Fifth Affiliated Hospital, Sun Yat-Sen University

Collaborator

Sun Yat-Sen University Cancer Center

Collaborator

Source ClinicalTrials.gov
Apply now